Fenquizone|CAS 20287-37-0|DC Chemicals

Cas No.:	20287-37-0
Chemical Name:	Fenquizone
Synonyms:	6-Quinazolinesulfonamide,7-chloro-1,2,3,4-tetrahydro-4-oxo-2-phenyl-;Fenquizone;7-chloro-4-oxo-2-phenyl-2,3-dihydro-1H-quinazoline-6-sulfonamide;7-Chlor-2-phenyl-6-sulfamoyl-1,2,3,4-tetrahydro-chinazolin-4-on;7-Chlor-2-phenyl-6-sulfonylamino-1,2-dihydro-3H-chinazolin-4-on;7-chloro-4-oxo-2-phenyl-1,2,3,4-tetrahydro-quinazoline-6-sulfonic acid amide;Fenchizone;fenchizone[dcit];Fenquizona;Fenquizonum;Idrolone;7-chloro-4-oxo-2-phenyl-2, 3-dihydro-1H-quinazoline-6-sulfonamide;(+/-)-7-CHLORO-1,2,3,4-TETRAHYDRO-4-OXO-2-PHENYL-6-QUINAZOLINESULFONAMIDE;Fenquizone [USAN:INN];EX-A6134;2-Phenyl-6-sulfonamido-7-chloro-1,2,3,4-tetrahydro-4-quinazolidone;FENQUIZONE [MI];LJ1U13R8IK;HY-126179;2-Phenyl-7-chloro-6-sulfamoyl-1,2,3,4-tetrahydro-4-quinazolinone;M.G. 13054;(+-)-7-Chloro-1,2,3,4-tetrahydro-4-oxo-2-phenyl-6-quinazolinesulfonamide;Fenquizone (USAN/INN);DTXSID10864933;DB13708;NS00052047;MG-13054;20287-37-0;EINECS 243-689-5;FENQUIZONE [MART.];AKOS040751791;Fenquizona [INN-Spanish];FENQUIZONE [WHO-DD];Fenquizonum [INN-Latin];CS-0092520;FENQUIZONE [INN];6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-4-oxo-2-phenyl-, (+-)-;UNII-LJ1U13R8IK;CHEMBL2106186;7-chloro-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinazoline-6-sulfonamide;FENQUIZONE [USAN];Fenchizone [DCIT];CHEBI:135435;6-QUINAZOLINESULFONAMIDE, 7-CHLORO-1,2,3,4-TETRAHYDRO-4-OXO-2-PHENYL-, (+/-)-;D04161;MS-25131;Q3742488;SCHEMBL309550;DBDTUXMDTSTPQZ-UHFFFAOYSA-N;DA-73334
SMILES:	ClC1C=C2C(C(=O)NC(C3C=CC=CC=3)N2)=CC=1S(N)(=O)=O
Formula:	C₁₄H₁₂N₃O₃Scl
M.Wt:	337.78138
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.